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Epstein–Barr virus (EBV) is the aetiological agent of infectious mononucleosis (IM) which is a common sequel to primary
EBV infection. Thereafter, the virus is maintained as a lifetime latent infection. Although the proteins expressed during the
latent EBV infection provide a rich source of immunogenic epitopes, very little is known about cytotoxic T lymphocyte (CTL)
control of primary EBV infection. The present report is based on an analysis of CTL clones derived from a patient suffering
from acute IM. An intriguing feature of six CTL clones that displayed an HLA-restricted pattern of cell lysis was their initial
coexpression of the T cell markers CD3, CD4, and CD8. Detailed analysis of one of these clones, which was restricted
through the class II MHC antigen DR2, revealed reactivity with an epitope within the EBV lytic cycle early antigen, BHRF1,
which corresponds to the C-terminal region of the protein (AGLTLSLLVICSYLFISRG) (residues 171–189). There have been
no previously published reports describing a CTL response during acute IM directed against an EBV lytic antigen. Interest-
ingly, the coexpression of CD4 and CD8 by these CTLs during acute IM suggests that CD3/CD4/CD8/ cortical thymocytic
precursor cells are recruited in order to overcome the EBV infection. q 1996 Academic Press, Inc.
Epstein-Barr virus (EBV) is the aetiological agent of ripheral blood of an individual (IS; HLA A2/24 A69 B27
B62 DR2 DR4) with clinically diagnosed acute IM follow-infectious mononucleosis (IM) and is widespread in hu-
man populations where it is carried by the majority of ing stimulation with an HLA-related lymphoblastoid cell
line (LCL) (HLA A2 A24 B51 B62 DR2 DR7 DQW1 DQW2individuals as a lifelong and largely asymptomatic infec-
tion. The acute phase of IM is characterised haematolog- DRW53). Recombinant IL-2 (20 units/ml) (9, 10) and 25%
(v/v) supernatant from MLA-144 cultures (ATCC TIB-201)ically by a marked T cell (CD4/ and CD8/) lymphocytosis
which includes both a nonspecific and a specific compo- were included at all stages of the cloning procedure to
minimise the apoptosis of activated T cells in culturenent (1, 2). During the infection a lytic virus cycle is estab-
lished in the oropharynx (3–5) while EBV latent antigens (11). Multiple spontaneous LCLs were also established
from the acute IM donor (12).are expressed in virus-infected B cells (6). Latent anti-
gens are known to provide a rich source of immunogenic A total of 172 T cell clones were established of which
6 displayed a pattern of target recognition suggestive ofepitopes in healthy immune individuals and these epi-
topes are predominantly recognised by CD8 CTLs in the HLA-restricted lysis, i.e., the CTL lysed a spontaneous
LCL and failed to recognise allogeneic, non-HLA-relatedcontext of MHC class I restricting alleles. This CTL re-
sponse is believed to control the level of EBV-infected LCLs (data not shown). The phenotype of these 6 clones
was analysed for CD3, CD4, and CD8 expression usingcells in healthy virus carriers (7) and may also play an
important role in restricting the proliferation of virus-in- FACScan analysis 10 weeks after initiation of cultures. A
curious result was revealed in that the majority of clonesfected B cells in acute IM. Unlike the latent antigens,
however, lytic antigens have not been shown to evoke displayed a very high percentage of cells coexpressing
CD3, CD4, and CD8 molecules. Greater than 95% of Ta protective CTL response in acute EBV infection. The
present study was designed to determine a role for EBV cells from clones IS1 and IS7 were CD4/CD8 coexpres-
sers (Table 1 and Fig. 1) and this pattern of expressionlytic antigens during acute IM.
T cell clones were established (8) from the fresh pe- was also observed on 65% of cells from clones IS3,
IS8, and IS20 (Table 1). These 6 clones were further
screened against the panel of spontaneous LCLs to iden-1 To whom correspondence and reprint requests should be ad-
tify an autologous LCL refractory to lysis (data notdressed at Department of Medicine, The University of Queensland,
Royal Brisbane Hospital, Brisbane 4006, Australia, Fax: 61 7 3655462. shown). There was considerable heterogeneity in the
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TABLE 1
Percentage of IS CTL Clones Expressing CD3, CD4, and CD8 as Determined by FACScan Analysis
IS T cell clone
Phenotype IS1 IS3 IS4 IS7 IS8 IS20
Total CD8/ 99.20 71.33 35.45 98.92 94.02 95.73
Total CD4/ 99.20 97.32 95.16 96.06 68.87 85.33
Total CD3/ 99.68 99.97 99.93 99.99 78.35 98.13
CD304/80 0.00 0.00 0.00 0.00 0.00 0.00
CD3/4/80 0.00 28.64 63.75 0.76 1.65 0.31
CD30408/ 0.00 0.00 0.00 0.00 14.64 0.42
CD3/408/ 0.00 2.64 4.11 3.61 12.16 10.30
CD304/8/ 0.24 0.00 0.00 0.00 2.89 0.10
CD3/4/8/ 98.96 68.65 31.35 95.31 65.04 84.91
CD304080 0.08 0.00 0.00 0.00 4.12 1.35
capability of these LCLs to be lysed, but one LCL (IS/ of 90% of the cells was CD3/CD4/ but CD80 (data
not shown). An analysis of allogeneic target lysis andspon1C6) was identified which was not killed by any of
this panel of CTL clones. The most vigorously proliferat- inhibition with monoclonal antibodies specific for mono-
morphic determinants on class I and class II HLA anti-ing clone (IS7) was selected for further analysis of anti-
gen specificity using IS/spon1C6 as a host for vaccinia gens revealed that IS7 appeared to be restricted through
DR2 which was compatible with its dominant CD4 pheno-virus constructs expressing seven individual EBV latent
and lytic antigens (and vacc-TK0). This clone recognised type (data not shown).
To define the active epitope recognised by IS7, a pep-target cells infected with recombinant vaccinia virus en-
coding the BHRF1 gene product (Fig. 2). tide net of 20-mers overlapping by 10 amino acids span-
ning the BHRF1 protein was screened on autologous PHASubsequent FACS analyses of IS7 revealed that the
percentage of cells expressing both CD4 and CD8 de- blasts. Three consecutive experiments (representative ex-
periment Fig. 3) revealed that maximal activity was in-creased such that by Week 14 and beyond the phenotype
FIG. 1. CD3, CD4, and CD8 expression on CTL clones (A) DJM1 (control CD3/CD8/CD40) and (B) IS7 based on FACScan analysis (Becton–
Dickinson; Lysis II software). In each graph, the label for the x axis corresponds to the first component of that graph’s title. 3-colour cytofluorographic
analysis of T cells was performed by means of direct immunofluorescence using labelled monoclonal antibodies specific for CD3 (Tri-colour-
conjugated), CD4 (fluorescein-conjugated), and CD8 (phycoerythrin-conjugated) (Caltag Laboratories).
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by the lack of an autologous cell line supporting expres-
sion of EBV lytic cycle antigens which are required as a
stimulatory population for in vitro expansion of CTL. In
the present study, LCLs from the donor’s father were
available as an initial stimulating population and these
were later substituted with autologous spontaneous LCL.
It is interesting that both of these individuals shared the
class II restricting allele, DR2. Although only a small pro-
portion (usually 10%) of these LCL express lytic anti-
gens when examined by conventional techniques, the
exquisite sensitivity by which CTLs recognise peptide
fragments from viral antigen raises the possibility that
low levels of BHRF1 could be processed and presented
as target epitopes on LCLs.
It is interesting that another MHC class II-restricted
epitope has been identified within BHRF1 from this labo-
FIG. 2. Recognition of EBV protein encoded by recombinant vaccinia
constructs. Target cells were spontaneous LCLs (IS/spon1C3 and 1C6)
established from IM donor IS by limiting dilution of unfractionated mo-
nonuclear cells (19). IS/spon1C6 cells were infected with vaccinia virus
recombinants at a virus concentration of 10 PFU per cell and incubated
at 377 for 1 hr. After 14–16 hr, cells were washed and incubated with
Na251CrO4 for 90 min, washed three times, and used as targets in a
standard 5-hr 51Cr-release assay (at an E:T ratio of 10:1) (8). All EBV
sequences were derived from the B95.8 strain of virus (20). Constructs
encoding for the latent proteins EBNAs 1 and 3 (designated vacc-EBNA
1, etc.) and the lytic antigens BZLF1 and BHRF1 were generated as
previously described (21– 23) by standard methods of vector insertion
into the vaccinia virus thymidine kinase (TK) gene; expression of the
introduced EBV sequence was in each case under the control of the
vaccinia virus P7.5 early–late promoter. The vacc-gp350 recombinant
contains the full length open reading frame derived from pMA102 (24)
by excision with SmaI. The 2.8-kb fragment was isolated and ligated
into the SmaI site of pSC11. Vacc-gp110 was produced by excising the
genomic fragment encoding gp110 from pTZ19R (25) with BamHI and
EcoRI. The ends were repaired and inserted into the SmaI site of
pSC11. The vacc-gp85 construct was produced by excising the geno-
mic fragment encoding gp85 from pTZX2 (25) with SmaI and HincII.
This fragment was inserted into the SmaI site of pSC11. All constructs
had the potential to encode the relevant full-length EBV protein. A
vaccinia construct negative for thymidine kinase (vacc-TK0) with no
EBV genes was used as a control.
FIG. 3. Recognition of peptide-sensitised autologous phytohaemag-
glutinin (PHA)-stimulated T cell blasts (PHA blasts) by BHRF1-specific
cluded in peptide 30 (AGLTLSLLVICSYLFISRG) (residues CTL clone IS7. PHA blasts were established from IM donor IS as
171–189) although the overlapping peptide 29 (SRRFSW- described previously (26). The panel of synthetic peptides of 19 or 20
amino acids in length which spanned the BHRF1 protein and over-TLFLAGLTLSLLVI) and peptide 16 (LDFNSVFLEIFHRGD-
lapped by 10 amino acids were synthesized (27) based on the knownPSLGR) were also consistently recognised to a lesser
BHRF1 protein sequence of the B95.8 strain of virus. These peptidesdegree. It is relevant to note that peptide 30 and peptide
were employed as targets in cytotoxicity assays by incubating them
16 conform with the published DR2 motif (13). with 51Cr-labelled PHA blasts for 1 hr at 377. IS7 CTL were then added
The definition of the importance of these antigens in and the assay conducted as described in Fig. 2. A significant level of
lysis is considered to be 10% (dashed line).CTL control of acute EBV infection has been hampered
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